Historical record - last NADAC effective date: 9/18/2024
Product Information
ERYTHROMYCIN ES 400 MG TAB is a generic product labeled by Azurity Pharmaceuticals Inc., priced at $11.7351 per EA under NDC 24338011003. Its NADAC has been published 74 times since Apr 17, 2024.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is BX.
Strength
400 mg/1
Manufacturer
Azurity Pharmaceuticals Inc.NDC
24338011003
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/18/2024
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA061904FDA Approved
Before 1982
TE Code
BX
On Market Since
10/3/2011
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN ES 400 MG TAB has been published 74 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.7351 per EA |
|---|---|
| All-time high | $11.7351 (Sep 10, 2025) |
| All-time low | $11.6852 (Apr 17, 2024) |
| Median price | $11.7351 |
| Average price | $11.7289 |
| Largest weekly change | +0.2% (Jul 17, 2024) |
| Weeks tracked | 74 |
| Tracking since | Apr 17, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+0.4%
Last surveyed Sep 10, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Erythromycin Ethylsuccinate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin Ethylsuccinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN ES 400 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN ES 400 MG TAB, manufactured by Azurity Pharmaceuticals Inc., is $11.7351 per EA (NDC 24338011003), effective Sep 10, 2025.
How has the price of ERYTHROMYCIN ES 400 MG TAB changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN ES 400 MG TAB has held within roughly two percent of its current level. It has been tracked across 74 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN ES 400 MG TAB?
Since Apr 17, 2024, the NADAC for ERYTHROMYCIN ES 400 MG TAB has ranged from a low of $11.6852 (Apr 17, 2024) to a high of $11.7351 (Sep 10, 2025), with a median of $11.7351 per EA.
Are there cheaper alternatives to ERYTHROMYCIN ES 400 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of ERYTHROMYCIN ES 400 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ERYTHROMYCIN ES 400 MG TAB?
ERYTHROMYCIN ES 400 MG TAB (NDC 24338011003) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a generic product.